BioSpace News Archive

Kepley BioSystems filed the second of two recent patents describing novel approaches to protective applications addressing the Coronavirus pandemic, as well as increasing antimicrobial resistance threats. Kepley researchers have invented a method to permanently infuse a substrate with antimicrobial functional fullerenes. Appli

- Upadacitinib (15 mg and 30 mg) monotherapy showed significant improvement in skin clearance and reduction in itch at week 16 in adult and adolescent patients with moderate to severe atopic dermatitis versus placebo[1] - Safety results were consistent with those of its replicate study, Measure Up 1[2] - RINVOQ, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is being studied as a once-daily oral therapy for moderate to severe atopic dermatitis an

ProciseDx Inc. has raised $10.5m through $8.5m of equity and $2m of debt, to fund ongoing development and commercialization of its point-of-care (POC) diagnostic platform.

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the proposed public offerings described below. The completion of the proposed public offerings is subject to market and other factors. BioNTech announced the commencement of a firm commitment underwritten offering (the “Underwritten Offering”) of 5,000,000 American Depositary Shares (“ADSs”), each representing one of its ordinary shares. In connection with the Underwri

SEngine Precision Medicine announced that data supporting the clinical utility of the PARIS® Test was highlighted in a prospective study in colorectal cancer patients with peritoneal metastases.

FUJIFILM Sonosite, Inc. , specialists in developing cutting-edge point-of-care ultrasound (POCUS) solutions, and part of the larger Fujifilm Healthcare portfolio, has announced the launch of the new Sonosite PX ultrasound system. Sonosite PX is the next generation in Sonosite POCUS, with the most advanced image clarity ever seen in

An estimated 37 million American adults are affected by kidney disease but 90% are unaware they even have it.

Orphazyme expects to submit MAA for arimoclomol for NPC to European Medicines Agency in the second half of 2020 Arimoclomol progressing through registrational trials in two additional indications - ALS and sIBM

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has received a positive opinion on European Orphan Drug Designation for SLS-005 in Sanfilippo syndrome from the European Medicines Agency (EMA

Sorrel Medical (sorrelmedical.com), an Eitan Group Company, a developer and manufacturer of wearable drug delivery devices, today announced it has entered into a strategic partnership with one of the world’s leading pharmaceutical companies to advance the development and introduction of next-generation wearable drug delivery solutions.